Topical Drug Delivery Market (By Product: Semi-Solid Formulations, Liquid Formulations, Solid Formulations, Transdermal Products; By Route of Administration: Oral, Injectable, Dermal, Ocular, Pulmonary, Implantable, Transmucosal, Nasal; By End User: Home Care Settings, Hospitals & Clinics, Burn Centers, Other Facilities) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032
Topical Drug Delivery Market
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Topical Drug Delivery Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Topical Drug Delivery Market Revenue and Volume, by Product, 2024-2033
8.1.1 Semi-Solid Formulations
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Liquid Formulations
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
8.1.3. Solid Formulations
8.1.3.1. Market Revenue and Volume Forecast (2021-2033)
8.1.4. Transdermal Products
8.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1. Topical Drug Delivery Market Revenue and Volume, by Route of Administration, 2024-2033
9.1.1. Oral
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Injectable
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Dermal
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
9.1.4. Ocular
9.1.4.1. Market Revenue and Volume Forecast (2021-2033)
9.1.5. Pulmonary
9.1.5.1. Market Revenue and Volume Forecast (2021-2033)
9.1.6. Implantable
9.1.6.1. Market Revenue and Volume Forecast (2021-2033)
9.1.7. Transmucosal
9.1.7.1. Market Revenue and Volume Forecast (2021-2033)
9.1.8. Nasal
9.1.8.1. Market Revenue and Volume Forecast (2021-2033)
10.1. Topical Drug Delivery Market Revenue and Volume, by End User, 2024-2033
10.1.1. Home Care Settings
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Hospitals & Clinics
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Burn Centers
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1.4. Other Facilities
10.1.4.1. Market Revenue and Volume Forecast (2021-2033)
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by End User (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by End User (2021-2033)
12.1. Johnson & Johnson
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Novartis International AG
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. F. Hoffmann-La Roche AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Pfizer Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Antares Pharma, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. GlaxoSmithKline plc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. 3M (US)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Merck & Co., Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Sanofi
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample